Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Receivables (2021 - 2026)

Kiniksa Pharmaceuticals International filings provide 6 years of Receivables readings, the most recent being $23.2 million for Q1 2026.

  • On a quarterly basis, Receivables fell 42.03% to $23.2 million in Q1 2026 year-over-year; TTM through Mar 2026 was $23.2 million, a 42.03% decrease, with the full-year FY2025 number at $15.6 million, down 62.63% from a year prior.
  • Receivables hit $23.2 million in Q1 2026 for Kiniksa Pharmaceuticals International, up from $15.6 million in the prior quarter.
  • In the past five years, Receivables ranged from a high of $51.7 million in Q3 2025 to a low of $3.0 million in Q3 2023.
  • Median Receivables over the past 5 years was $21.3 million (2023), compared with a mean of $23.0 million.
  • Biggest five-year swings in Receivables: plummeted 74.78% in 2023 and later soared 718.41% in 2024.
  • Kiniksa Pharmaceuticals International's Receivables stood at $20.3 million in 2022, then grew by 4.68% to $21.3 million in 2023, then surged by 96.2% to $41.7 million in 2024, then tumbled by 62.63% to $15.6 million in 2025, then surged by 48.93% to $23.2 million in 2026.
  • The last three reported values for Receivables were $23.2 million (Q1 2026), $15.6 million (Q4 2025), and $51.7 million (Q3 2025) per Business Quant data.